Adventia Pharma, Pharmaceutical laboratory specialized in medical nutrition, has advanced in the understanding of malnutrition problems as a consequence of chronic pathologies and especially in relation to chronic kidney disease in hemodialysis and Crohn's disease.

Malnutrition is a common consequence in a significant number of patients with these chronic diseases and to support their treatment, Adventia Pharma has led the SUNESPRO Project since 2017. A Research and Development project that aims to design a diet with specific and evident bioactive activity for each of them.

Specifically in the case of chronic kidney diseases, Adventia's advances have been aimed at compensating for protein malnutrition, obtaining a diet with a high percentage of highly absorbed proteins that, without harming the kidney function of the patient, makes it possible for nutritional support be suitable for diabetic patients.

In the case of Crohn's disease, Adventia has focused on the incorporation of amino acids and fatty acids with intestinal anti-inflammatory activity. Compounds that facilitate the digestion of the ingredients of the nutritional support, positively affecting the main cause of the disease. 

The scope of these Adventia Pharma developments may positively affect people who suffer from chronic kidney disease and require Replacement Renal Treatment such as dialysis, hemodialysis and transplantation.

The SUNESPRO project has had the collaboration of the Biopolis company, in charge of providing the probiotics included in the Adventia formulations, being researchers from the Jiménez Díaz Foundation Health Research Institute (FIIS-FJD) and the Andalusian Public Foundation for Research in Biomedicine and Health (FIMABIS) those responsible for clinical trials.

El SUNESPRO project It has been financed by: FEDER Ministry of Science, Innovation and Universities - State Research Agency (Project RTC-2017-5959-1).